Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-induced depression in chronic hepatitis C.

Y Horsmans1

  • 1Department of Gastroenterology, Cliniques Universitaires Saint-Luc Université Catholique de Louvain, Belgium. horsmans@gaen.ucl.ac.be

The Journal of Antimicrobial Chemotherapy
|September 5, 2006
PubMed
Summary

Antiviral therapy for chronic hepatitis C (HCV) can cause depression and neuro-psychiatric symptoms, particularly with pegylated interferon (IFN). However, selective serotonin reuptake inhibitors (SSRIs) may mitigate these effects, improving treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypogammaglobulinemia, a new risk factor for hepatitis B virus reactivation : about two cases.

Acta gastro-enterologica Belgica·2023
Same author

Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.

Acta gastro-enterologica Belgica·2021
Same author

Hepatitis C virus (HCV) prevalence estimation in the adult general population in Belgium : a meta-analysis.

Acta gastro-enterologica Belgica·2020
Same author

Impact of liver inflammation on whole body insulin resistance : a case report on primary biliary cholangitis.

Acta gastro-enterologica Belgica·2020
Same author

Results of a screening campaign for hepatitis C viral infection in a Brussels hospital : do we need to go further?

Acta gastro-enterologica Belgica·2019
Same author

Immunisation after hepatitis B polyvalent vaccination among children in South Kivu Province, Democratic Republic of the Congo.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2019

Area of Science:

  • Hepatology
  • Neuroscience
  • Pharmacology

Background:

  • Chronic hepatitis C (HCV) treatment success rates are rising.
  • Depression and neuro-psychiatric symptoms are significant side effects of HCV antiviral therapy.
  • Pre-existing psychiatric conditions may be exacerbated by HCV infection itself.

Purpose of the Study:

  • To investigate the neuro-psychiatric side effects of chronic hepatitis C antiviral therapy.
  • To evaluate the impact of pegylated interferon (IFN) on mental health in HCV patients.
  • To assess the efficacy of selective serotonin reuptake inhibitors (SSRIs) in managing these side effects.

Main Methods:

  • Review of clinical trials and expert claims regarding HCV therapy side effects.
  • Analysis of the impact of pegylated interferon (IFN) on neuro-psychiatric symptoms.

Related Experiment Videos

  • Examination of the potential role of selective serotonin reuptake inhibitors (SSRIs) in mitigating side effects.

    • Main Results:

    • Pegylated interferon (IFN) administration significantly increases the incidence and severity of neuro-psychiatric symptoms in HCV patients.
    • Recent clinical trials suggest that selective serotonin reuptake inhibitors (SSRIs) can effectively manage these side effects.
    • The precise pathogenesis remains unclear, but IFN's impact on glucocorticoid and serotonin 1A receptors is implicated.

    Conclusions:

    • Antiviral therapy for HCV, especially with pegylated interferon (IFN), necessitates careful monitoring for neuro-psychiatric side effects.
    • The use of selective serotonin reuptake inhibitors (SSRIs) offers a promising strategy to manage depression and other psychiatric symptoms, allowing more patients to complete treatment.
    • Further research into the pathogenesis of these side effects is crucial for optimizing HCV treatment protocols.